FDA pharmacologic class
PCSK9 inhibitors
2 medicines are in FDA's class of pcsk9 inhibitors (pcsk9 inhibitors): evolocumab (Repatha) and alirocumab (Praluent). 0 of the 2 are listed from generic labelers (FDA NDC Directory, October 8, 2026). The lowest pharmacy cost is praluent 150 mg/ml pen at $258.01 per mL (NADAC).
Which medicines are pcsk9 inhibitors?
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Evolocumab | Repatha | none listed | $281.96 per mL 140 mg/mL sureclick | No | No current entry | 0 |
| Alirocumab | Praluent | none listed | $258.01 per mL 150 mg/mL pen | No | No current entry | 0 |
Source: FDA Established Pharmacologic Class (NDC Directory, openFDA); CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)
What do pharmacies pay?
Each medicine's most widely listed form, per unit, in the NADAC survey: what pharmacies paid, not what a patient pays; strengths differ, so compare like with like.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price